Orexo

Country:
Sector:
Market cap (m):
Sweden
Healthcare
SEK 2,407.85
Bloomberg:
Reuters:
Website:
ORX SS
ORX.ST
Share price (close):
SEK 66.60

Latest Reports

31 JAN 2020
Commissioned Research: Modest outlook for 2020
While Q4 2019 marked another quarter of solid growth (Zubsolv US revenues up 7.5% y/y organically), the company foresees flat y/y sales for Zubsolv in the US during 2020. To secure long-term growth, Orexo will continue investing in its pipeline, as confirmed by its outlook for an 8-18% y/y increase in opex – mostly driven by higher R&D spending. Based on this softer-than-anticipated outlook, we lower our sales forecast by 4-9% and adjust our DCF-based valuation range to SEK 70-80 (78-93) per share.

Analysts: Klas Pyk
25 OCT 2019
Commissioned Research: Q3 ticked many boxes
Once again Orexo proved its ability to leverage its operations by posting a Q3 report that ticked many boxes. Sales increased by 6.7% y/y, despite a challenging market. At the same time, both gross margins and underlying operating expenditure improved significantly. The strong performance resulted in an adjusted EBITDA margin uplift of 15.3 pp y/y. During the period, Orexo also announced a partnership agreement with the goal of broadening its portfolio with a new digital therapy for Opioid Use Disorder. We update our DCF-based fair value range to SEK 78-93 per share. - Marketing material commissioned by Orexo

Analysts: Klas Pyk
12 JUL 2019
Commissioned Research: Proving its resilience
There has been turbulence in the market where Orexo's flagship product, Zubsolv, is sold, but this had only a limited impact on Orexo's performance, however, increasing revenues by 6.7% y/y at CER. While Orexo continues to show solid revenue and earnings growth for its existing products (EBITDA up 19.4% y/y), it is also continuously evaluating and taking opportunities to broaden its product portfolio and geographical footprint. We reiterate our DCF-based valuation range of SEK 72-93 per share. Marketing material commissioned by Orexo.

Analysts: Klas Pyk
3 MAY 2019
Commissioned Research: H2 COGS reduction target already reached in Q1
Orexo posted a Q1 report with total revenue of SEK 174.3m versus SEK 139.7m in the same period last year, bang in line with our estimates. Zubsolv's US sales increased 9.3% y/y in local currency, to SEK 161.7m, spurred by improved market access. Ahead of schedule, Orexo reached its H2 2019 COGS-reduction target of 35% versus 2017 as early as Q1, which in turn bolstered margins in the quarter and contributes to our full-year positive estimate revisions (2019 EBIT estimates up by 19%). We increase our DCF-based valuation range to SEK 72-93 (64-84).

Analysts: Klas Pyk
1 APR 2019
Commissioned Research: Court ruling does not impact earnings potential
On 29 March, Orexo announced that the United States District Court for the District of Delaware has ruled that Actavis' generic versions of Suboxone and Subutex tablets do not infringe Orexo's US Patent 8,454,996. Provided that the ruling stands, this means that Orexo will not receive any compensation from Actavis. We did not include a successful outcome in the litigation trial in our estimates and therefore reiterate our DCF-based fair value range of SEK 64-84 per share. Marketing material commissioned by Orexo.

Analysts: Klas Pyk
31 JAN 2019
Commissioned Research: Improved operational leverage in 2019
Orexo posted a Q4 report with total revenue of SEK 227.1m, versus SEK 191m in the same period last year. This sales growth was driven solely by Zubsolv in the US, which reached revenue of SEK 166.7m, up by 21.3% y/y in local currency. We view the continued solid uptake for Zubsolv in the US as positive, but its total revenues missed our expectations by around 5%. We attribute the miss to higher-than-expected rebates and lower demand for Abstral. In the report, last year's opex outlook at around SEK 500m was reiterated for 2019, implying solid operating leverage. Marketing material commissioned by Orexo

Analysts:
10 DEC 2018
Commissioned Research: CMD points to bright long-term prospects
Orexo announced new strategic objectives at its well-attended capital markets day. A comprehensive agenda and a mix of internal and external speakers bolster our confidence in our positive outlook for the company for 2019 and beyond. Our DCF-based fair value range is SEK 64-84 per share. – Marketing material commissioned by Orexo

Analysts:
30 OCT 2018
Commissioned Research: Strong outlook clouded by legal expenses
Orexo's Q3 report showed continued strong performance for the Zubsolv US business, but slow initial uptake of Zubsolv in Europe and higher legal expenses than we had expected. Therefore, we make slight negative revisions to our near-term Zubsolv sales forecast for the EU and assume somewhat higher costs. However, a solid performance and outlook for Zubsolv in the US, coupled with improved guidance for the manufacturing efficiency programme, reaffirms the long-term prospects. Marketing material commissioned by Orexo.

Analysts:
22 OCT 2018
Commissioned Research: Waiting for a major product deal
Recent Zubsolv prescription data shows a development broadly in line with our expectations and, ahead of the Q3 report, we only make a slight downward correction to our H2 estimates. In the coming months, we will closely monitor early European Zubsolv sales, the US market access situation and potential product acquisitions, as the US commercial platform was further developed by internalising the entire sales force in October. – Marketing material commissioned by Orexo

Analysts:
12 SEP 2018
Commissioned Research: US appeal case won – shares up 75% in 24 hours
Orexo won its appeal case confirming Zubsolv's US intellectual property protection until 2032, preventing early competition from Actavis's generics in 2019. This decision frees up considerable resources to focus on business development instead. The rapid ~75% share price appreciation also supports Orexo's M&A firepower beyond its cash position of SEK 0.5bn. - Marketing material commissioned by Orexo

Analysts:

Equity analysts

Analyst

Key persons

CEO: Nikolaj Sørensen

CFO: Joseph DeFeo

Chairman: Martin Nicklasson

Numbers
Nordea
SEKm
2016
2017
2018
2019
2020E
2021E
2022E
Total revenues
705.9
643.7
783.1
844.8
816.4
851.5
n.a.
Ebitda (adj.)
74.40
78.20
116.60
223.60
173.55
240.97
n.a.
Ebitda - margin
10.5%
12.1%
14.9%
26.5%
21.3%
28.3%
n.a.
EBIT (adj.)
51.7
57.4
95.8
182.6
147.0
212.9
n.a.
EBIT (adj.) margin
7.3%
8.9%
12.2%
21.6%
18.0%
25.0%
n.a.
PTP (adj.)
35.6
29.7
92.3
179.3
156.4
225.4
n.a.
Net profit from cont oper (adj)
29.10
23.20
138.00
170.50
140.76
202.86
n.a.
Shareholders´ Equity
310.3
329.1
476.1
706.4
847.2
1,050.0
n.a.
Net interest bearing debt
115.4
-8.8
-269.2
-472.5
-627.0
-845.8
n.a.
Net gearing
37.2%
-2.7%
-56.5%
-66.9%
-74.0%
-80.5%
n.a.
Net debt/EBITDA
1.6
-0.1
-2.3
-2.1
-3.6
-3.5
n.a.
Free cash flow to equity
71.1
59.6
235.9
264.5
169.9
241.4
n.a.
Diluted number of shares in issue, year-end (m)
34.6
34.7
35.2
35.4
35.4
35.4
n.a.
Nordea Markets estimates published on Jan 31, 2020
Source: Company data, Nordea estimates
Per share data and multiples
Nordea
SEK and %
2016
2017
2018
2019
2020E
2021E
2022E
EPS (adj.)
0.84
0.67
3.92
4.82
3.98
5.74
n.a.
EPS (adj.) growth
114.7%
-20.5%
485.5%
23.0%
-17.4%
44.1%
n.a.
DPS
0.00
0.00
0.00
0.00
0.00
0.00
n.a.
BVPS
9.0
9.5
13.5
20.0
24.0
29.7
n.a.
P/E (adj.)
44.7
61.6
15.0
13.0
16.7
11.6
n.a.
EV/Sales
2.01
2.21
2.30
2.07
2.12
1.77
n.a.
EV/EBITDA (adj.)
19.02
18.15
15.45
7.82
9.96
6.27
n.a.
EV/EBIT (adj.)
27.38
24.73
18.81
9.58
11.76
7.09
n.a.
P/BV
4.19
4.34
4.35
3.14
2.78
2.24
n.a.
Dividend yield
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
n.a.
FCF Yield bef A&D, lease adj
5.0%
4.3%
11.7%
13.1%
7.2%
10.2%
n.a.
RoE
10.0%
7.3%
34.3%
28.8%
18.1%
21.4%
n.a.
ROIC
6.4%
8.1%
15.0%
29.1%
23.1%
34.4%
n.a.
Nordea Markets estimates published on Jan 31, 2020
Source: Company data, Nordea estimates

Source: Thomson Reuters